Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer

被引：0
|
作者：
Dimitrios Pectasides
Vasilios Karavasilis
George Papaxoinis
Georgia Gourgioti
Thomas Makatsoris
Georgia Raptou
Eleni Vrettou
Joseph Sgouros
Epaminontas Samantas
George Basdanis
Pavlos Papakostas
Dimitrios Bafaloukos
Vassiliki Kotoula
Haralambos P. Kalofonos
Chrisoula D. Scopa
George Pentheroudakis
George Fountzilas
机构：
[1] “Hippokration” Hospital,Oncology Section, Second Department of Internal Medicine
[2] Aristotle University of Thessaloniki School of Medicine,Department of Medical Oncology, “Papageorgiou” Hospital
[3] Section of Biostatistics,Division of Oncology, Department of Medicine
[4] Hellenic Cooperative Oncology Group,Department of Pathology
[5] Data Office,Third Department of Medical Oncology
[6] University Hospital,First Propaedeutic Department of Surgery, “AHEPA” Hospital
[7] University of Patras Medical School,Department of Medical Oncology
[8] Aristotle University of Thessaloniki School of Medicine,First Department of Medical Oncology
[9] “Agii Anargiri” Cancer Hospital,Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research
[10] Aristotle University of Thessaloniki School of Medicine,Department of Pathology
[11] “Hippokration” Hospital,Department of Medical Oncology
[12] “Metropolitan” Hospital,undefined
[13] Aristotle University of Thessaloniki School of Medicine,undefined
[14] University Hospital,undefined
[15] University of Patras Medical School,undefined
[16] Ioannina University Hospital,undefined
来源：
BMC Cancer | / 15卷
关键词：
Colorectal cancer; Adjuvant chemotherapy; Modified FOLFOX6; Capecitabine; Oxaliplatin; Prognosis; KRAS; Microsatellite instability;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Safety and Efficacy of Adjuvant Therapy with Oxaliplatin, Leucovorin and 5-Fluorouracil After Mesorectal Excision with Lateral Pelvic Lymph Node Dissection for Stage III Lower Rectal Cancer
    Iwasa, Satoru
    Souda, Hiroaki
    Yamazaki, Kentaro
    Takahari, Daisuke
    Miyamoto, Yuji
    Takii, Yasumasa
    Ikeda, Satoshi
    Hamaguchi, Tetsuya
    Kanemitsu, Yukihide
    Shimada, Yasuhiro
    ANTICANCER RESEARCH, 2015, 35 (03) : 1815 - 1819
  • [22] Health-related quality of life and cost comparison of adjuvant capecitabine versus 5-fluorouracil/leucovorin in stage III colorectal cancer patients
    Hong-Hwa Chen
    William Tzu-Liang Chen
    Hsin-Chung Lee
    Jen-Kou Lin
    Chuan-Yin Fang
    Yenn-Hwei Chou
    Peng-Chan Lin
    Bo-Wen Lin
    Chi-Chou Huang
    Chung-Hung Yeh
    Hsi-Hsien Hsu
    Hung-Chang Chen
    Wen-Chien Ting
    Ming-Chin Yang
    Elise Chia-Hui Tan
    Quality of Life Research, 2015, 24 : 473 - 484
  • [23] Efficacy of Adjuvant 5-Fluorouracil Therapy for Patients with EMAST-Positive Stage II/III Colorectal Cancer
    Hamaya, Yasushi
    Guarinos, Carla
    Tseng-Rogenski, Stephanie S.
    Iwaizumi, Moriya
    Das, Ritabrata
    Jover, Rodrigo
    Castells, Antoni
    Llor, Xavier
    Andreu, Montserrat
    Carethers, John M.
    PLOS ONE, 2015, 10 (05):
  • [24] A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment
    Nikol Snoeren
    Emile E Voest
    Andre M Bergman
    Otilia Dalesio
    Henk M Verheul
    Rob AEM Tollenaar
    Joost RM van der Sijp
    Sander B Schouten
    Inne HM Borel Rinkes
    R van Hillegersberg
    BMC Cancer, 10
  • [25] Oxaliplatin in combination with infusional 5-fluorouracil and leucovorin every 2 weeks as first-line treatment in patients with advanced colorectal cancer: A phase II study
    Kouroussis, C
    Souglakos, J
    Kakolyris, S
    Mavroudis, D
    Malamos, N
    Kalbakis, K
    Androulakis, N
    Agelaki, A
    Vardakis, N
    Samonis, G
    Georgoulias, V
    ONCOLOGY, 2001, 61 (01) : 36 - 41
  • [26] Randomized phase II study of tegafur–uracil/leucovorin versus tegafur–uracil/leucovorin plus oxaliplatin after curative resection of high-risk stage II/III colorectal cancer (SOAC-1101 trial)
    Chihiro Kosugi
    Keiji Koda
    Nobuhiro Takiguchi
    Satoru Takaishi
    Hideaki Miyauchi
    Nobuo Hirayama
    Yukihiro Nomura
    Eisuke Kondo
    Yohei Kawasaki
    Yoshihito Ozawa
    Hisahiro Matsubara
    International Journal of Colorectal Disease, 2021, 36 : 1739 - 1749
  • [27] Phase II trial evaluating the long-term efficacy and peripheral sensory neuropathy of capecitabine plus oxaliplatin (XELOX) as adjuvant therapy in Japanese patients with operated stage III colon cancer
    Hata, Taishi
    Uemura, Mamoru
    Danno, Katsuki
    Yoshioka, Shinichi
    Matsuda, Chu
    Kagawa, Yoshinori
    Shingai, Tatsushi
    Suzuki, Yozo
    Tei, Mitsuyoshi
    Tanida, Tsukasa
    Komori, Takamichi
    Okamura, Shu
    Ota, Hirofumi
    Takemoto, Hiroyoshi
    Ogino, Takayuki
    Miyoshi, Norikatsu
    Yamamoto, Hirofumi
    Murata, Kohei
    Doki, Yuichiro
    Eguchi, Hidetoshi
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [28] Randomized phase II study of tegafur-uracil/leucovorin versus tegafur-uracil/leucovorin plus oxaliplatin after curative resection of high-risk stage II/III colorectal cancer (SOAC-1101 trial)
    Kosugi, Chihiro
    Koda, Keiji
    Takiguchi, Nobuhiro
    Takaishi, Satoru
    Miyauchi, Hideaki
    Hirayama, Nobuo
    Nomura, Yukihiro
    Kondo, Eisuke
    Kawasaki, Yohei
    Ozawa, Yoshihito
    Matsubara, Hisahiro
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2021, 36 (08) : 1739 - 1749
  • [29] Initial Safety Report of NSABP C-08: A Randomized Phase III Study of Modified FOLFOX6 With or Without Bevacizumab for the Adjuvant Treatment of Patients With Stage II or III Colon Cancer
    Allegra, Carmen J.
    Yothers, Greg
    O'Connell, Michael J.
    Sharif, Saima
    Colangelo, Linda H.
    Lopa, Samia H.
    Petrelli, Nicholas J.
    Goldberg, Richard M.
    Atkins, James N.
    Seay, Thomas E.
    Fehrenbacher, Louis
    O'Reilly, Seamus
    Chu, Luis
    Azar, Catherine A.
    Wolmark, Norman
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (20) : 3385 - 3390
  • [30] S-1 and Oxaliplatin Versus Tegafur-uracil and Leucovorin as Postoperative Adjuvant Chemotherapy in Patients With High-risk Stage III Colon Cancer (ACTS-CC 02): A Randomized, Open-label, Multicenter, Phase III Superiority Trial
    Sunami, Eiji
    Kusumoto, Tetsuya
    Ota, Mitsuyoshi
    Sakamoto, Yoshiyuki
    Yoshida, Kazuhiro
    Tomita, Naohiro
    Maeda, Atsuyuki
    Teshima, Jin
    Okabe, Michio
    Tanaka, Chihiro
    Yamauchi, Junichiro
    Itabashi, Michio
    Kotake, Kenjiro
    Takahashi, Keiichi
    Baba, Hideo
    Boku, Narikazu
    Aiba, Keisuke
    Ishiguro, Megumi
    Morita, Satoshi
    Takenaka, Naruhito
    Okude, Ryota
    Sugihara, Kenichi
    CLINICAL COLORECTAL CANCER, 2020, 19 (01) : 22 - +
12345